SG10201607787RA - Vaccine Composition Comprising An Inactivated Chikungunya Virus Strain - Google Patents
Vaccine Composition Comprising An Inactivated Chikungunya Virus StrainInfo
- Publication number
- SG10201607787RA SG10201607787RA SG10201607787RA SG10201607787RA SG10201607787RA SG 10201607787R A SG10201607787R A SG 10201607787RA SG 10201607787R A SG10201607787R A SG 10201607787RA SG 10201607787R A SG10201607787R A SG 10201607787RA SG 10201607787R A SG10201607787R A SG 10201607787RA
- Authority
- SG
- Singapore
- Prior art keywords
- vaccine composition
- virus strain
- chikungunya virus
- inactivated
- inactivated chikungunya
- Prior art date
Links
- 241001502567 Chikungunya virus Species 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
- G01N2333/181—Alphaviruses or Group A arboviruses, e.g. sindbis, VEE, EEE, WEE or semliki forest virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
- G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
- G01N2333/185—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2067CH2011 | 2011-06-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201607787RA true SG10201607787RA (en) | 2016-11-29 |
Family
ID=46601866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201607787RA SG10201607787RA (en) | 2011-06-17 | 2012-06-18 | Vaccine Composition Comprising An Inactivated Chikungunya Virus Strain |
Country Status (12)
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201606635SA (en) * | 2012-02-16 | 2016-10-28 | Vlp Therapeutics Llc | Virus like particle composition |
| US9637532B2 (en) | 2013-07-12 | 2017-05-02 | Vlp Therapeutics, Llc | Virus like particle comprising PD-1 antigen or PD-1 ligand antigen |
| US10385101B2 (en) | 2014-08-08 | 2019-08-20 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein E3 |
| EP3177720B1 (en) | 2014-08-08 | 2021-09-22 | VLP Therapeutics, Inc. | Virus like particle comprising modified envelope protein e3 |
| EP3191589A4 (en) | 2014-09-11 | 2018-05-09 | VLP Therapeutics, LLC | Flavivirus virus like particle |
| KR102839410B1 (ko) * | 2015-07-16 | 2025-07-28 | 브하라트 바이오테크 인터내셔날 리미티드 | 백신 조성물 |
| WO2017123932A1 (en) * | 2016-01-13 | 2017-07-20 | United States, As Represented By The Secretary Of The Army | Inactived vaccine for chikungunya virus |
| CN105906694B (zh) * | 2016-05-05 | 2019-05-14 | 中国人民解放军军事医学科学院微生物流行病研究所 | 基孔肯亚病毒特异性检测抗原及其应用 |
| BR112018074277A2 (pt) | 2016-05-27 | 2019-10-01 | Univ Griffith | vacina de alfavírus artrogênica |
| KR101875055B1 (ko) * | 2016-10-19 | 2018-07-06 | 연세대학교 원주산학협력단 | 융합 단백질 및 그의 용도 |
| WO2018074884A1 (ko) * | 2016-10-20 | 2018-04-26 | 연세대학교 원주산학협력단 | 재조합 단백질 및 그의 용도 |
| KR102007203B1 (ko) * | 2016-10-20 | 2019-08-05 | 연세대학교 원주산학협력단 | 융합 단백질 및 그의 용도 |
| EP3684404A1 (en) * | 2017-09-21 | 2020-07-29 | Valneva SE | Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3 |
| AU2018359558C1 (en) | 2017-11-03 | 2022-09-22 | Takeda Vaccines, Inc. | Method for inactivating Zika virus and for determining the completeness of inactivation |
| CN116983398A (zh) | 2017-11-30 | 2023-11-03 | 武田疫苗股份有限公司 | 寨卡疫苗和免疫原性组合物以及其使用方法 |
| TW201930335A (zh) | 2017-12-20 | 2019-08-01 | 美商Ｖｌｐ醫療股份有限公司 | α病毒複製子顆粒 |
| WO2019148086A1 (en) * | 2018-01-26 | 2019-08-01 | The Wistar Institute Of Anatomy And Biology | Vaccines against mosquito-borne viruses, and methods of using same |
| CN109536464B (zh) * | 2018-12-10 | 2022-06-10 | 中国科学院武汉病毒研究所 | 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用 |
| KR102016668B1 (ko) | 2018-12-19 | 2019-08-30 | 주식회사 엠디헬스케어 | 치쿤군야 바이러스 e2에 특이적으로 결합하는 dna 압타머 및 이의 용도 |
| US11562105B2 (en) * | 2019-07-11 | 2023-01-24 | Yokogawa Electric Corporation | System and method for module engineering with sequence libraries |
| KR102202082B1 (ko) | 2019-09-25 | 2021-01-11 | 충북대학교 산학협력단 | 치쿤군야 바이러스의 외피단백질 도메인 ⅱ에 대해 특이적으로 결합하는 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도 |
| EP4135847A4 (en) | 2020-04-17 | 2024-05-15 | VLP Therapeutics, Inc. | Coronavirus vaccine |
| MX2022013638A (es) | 2020-04-30 | 2023-01-24 | Vlp Therapeutics Inc | Inmunoterapia con citocina. |
| CA3186812A1 (en) * | 2020-07-31 | 2022-02-03 | Replicate Bioscience, Inc. | Modified chikungunya viruses and sindbis viruses and uses thereof |
| CN117771353B (zh) * | 2024-02-27 | 2024-05-14 | 中国医学科学院医学生物学研究所 | 一种以包膜蛋白为靶标的基孔肯雅病毒的mRNA疫苗及其制备方法 |
| CN118561969B (zh) * | 2024-08-02 | 2024-11-19 | 中国医学科学院医学生物学研究所 | 一种通过优化全长结构蛋白序列设计的基孔肯雅病毒广谱性mRNA疫苗 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1922084A4 (en) | 2005-08-11 | 2011-01-12 | Univ Texas | INFECTIOUS CLONING OF CHICUNGUNYA VIRUS AND ITS USE |
| CN101516395B (zh) * | 2006-09-01 | 2014-03-26 | 伯哈拉特生物技术国际有限公司 | 抗屈曲病毒感染的疫苗 |
| JP2009149583A (ja) * | 2007-12-21 | 2009-07-09 | National Institute Of Biomedical Innovation | フラビウイルス感染症ワクチンおよびフラビウイルス感染症ワクチン用アジュバント |
| CN102317308A (zh) | 2008-11-26 | 2012-01-11 | 美国国有健康与人类服务部 | 类病毒组合物颗粒及其使用方法 |
-
2012
- 2012-06-18 EP EP12741389.6A patent/EP2720715B1/en active Active
- 2012-06-18 WO PCT/IN2012/000432 patent/WO2012172574A1/en active Application Filing
- 2012-06-18 SG SG10201607787RA patent/SG10201607787RA/en unknown
- 2012-06-18 AU AU2012269907A patent/AU2012269907B2/en active Active
- 2012-06-18 MY MYPI2013004491A patent/MY173117A/en unknown
- 2012-06-18 KR KR1020147000963A patent/KR101792684B1/ko active Active
- 2012-06-18 US US14/126,504 patent/US9844588B2/en active Active
- 2012-06-18 JP JP2014515342A patent/JP6147734B2/ja active Active
- 2012-06-18 BR BR112013032251-9A patent/BR112013032251B1/pt not_active IP Right Cessation
- 2012-06-18 CN CN201280029793.9A patent/CN103796676B/zh active Active
- 2012-06-18 PH PH1/2013/502621A patent/PH12013502621A1/en unknown
-
2013
- 2013-12-12 ZA ZA2013/09386A patent/ZA201309386B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MY173117A (en) | 2019-12-27 |
| EP2720715A1 (en) | 2014-04-23 |
| BR112013032251B1 (pt) | 2021-12-07 |
| US9844588B2 (en) | 2017-12-19 |
| WO2012172574A1 (en) | 2012-12-20 |
| US20140120125A1 (en) | 2014-05-01 |
| KR20140043784A (ko) | 2014-04-10 |
| AU2012269907B2 (en) | 2017-05-18 |
| KR101792684B1 (ko) | 2017-11-02 |
| JP6147734B2 (ja) | 2017-06-14 |
| JP2014520117A (ja) | 2014-08-21 |
| CN103796676A (zh) | 2014-05-14 |
| ZA201309386B (en) | 2014-08-27 |
| PH12013502621A1 (en) | 2014-02-03 |
| EP2720715B1 (en) | 2017-08-09 |
| CN103796676B (zh) | 2017-09-12 |
| BR112013032251A2 (pt) | 2016-12-20 |
| AU2012269907A1 (en) | 2014-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201309386B (en) | Vaccine composition comprising an inactivated chikungunya virus strain | |
| IL262123A (en) | Influenza virus vaccines and their uses | |
| IL235890A0 (en) | vaccine | |
| IL229307A0 (en) | Inactivated dengue virus vaccine | |
| ZA201404797B (en) | Influenza virus vaccines and uses thereof | |
| PL2935313T3 (pl) | Szczepionki przeciwko wirusowi zapalenia wątroby typu b | |
| IL222228A0 (en) | Hiv vaccine | |
| IL231043A (en) | vaccine | |
| PL2931304T3 (pl) | Szczepionka wt1 | |
| GB201119999D0 (en) | Vaccine | |
| SG11201502221WA (en) | Novel attenuated dengue virus strains for vaccine application | |
| ZA201404512B (en) | Malaria vaccine | |
| GB201006324D0 (en) | Vaccine | |
| GB201210226D0 (en) | Vaccine | |
| GB201120000D0 (en) | Vaccine | |
| GB201202090D0 (en) | Vaccine | |
| AU2013369626A1 (en) | Dengue virus vaccine composition | |
| HK40098029A (en) | Adjuvant and vaccine compositions | |
| SG11201505170WA (en) | Dengue virus vaccine composition | |
| ZA201302154B (en) | Vaccine | |
| HK1192850A (en) | Inactivated dengue virus vaccine | |
| GB201109294D0 (en) | Novel vaccine | |
| AU2011900657A0 (en) | Vaccine | |
| AU2012901774A0 (en) | Vaccine and uses thereof | |
| GB201121647D0 (en) | Vaccine |